Aarti Pharmalabs (NSE:AARTIPHARM) Construction In Progress: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AARTIPHARM Aarti Pharmalabs Ltd NSE:AARTIPHARM
54 GF Score
Price ₹888.70
GF Value ₹689.04
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Aarti Pharmalabs Construction In Progress?

Aarti Pharmalabs NSE:AARTIPHARM +0.57% 54 Construction In Progress is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:AARTIPHARM with a GF Score™ of 54/100 and a GF Value™ of ₹689.04 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Aarti Pharmalabs's quarterly construction in progress increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹3,052 Mil) but then declined from Mar. 2026 (₹3,052 Mil) to Jun. 2026 (₹0 Mil).

Aarti Pharmalabs's annual construction in progress increased from Mar. 2024 (₹908 Mil) to Mar. 2025 (₹3,293 Mil) but then declined from Mar. 2025 (₹3,293 Mil) to Mar. 2026 (₹3,052 Mil).

Aarti Pharmalabs Construction In Progress Historical Data

* Premium members only.

The historical data trend for Aarti Pharmalabs's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarti Pharmalabs Construction In Progress Chart

Aarti Pharmalabs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Construction In Progress
Get a 7-Day Free Trial 1,663.34 646.98 907.57 3,293.29 3,052.11

Aarti Pharmalabs Quarterly Data
Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1,605.03 0.00 3,052.11 0.00
NSE:AARTIPHARM
54GF Score
Aarti Pharmalabs Ltd NSE:AARTIPHARM
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarti Pharmalabs Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ₹0 Mil mean?
Aarti Pharmalabs (NSE:AARTIPHARM) has a Construction In Progress of ₹0 Mil as of Jun. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Aarti Pharmalabs and its competitors.
Is Aarti Pharmalabs' Construction In Progress too high?
Aarti Pharmalabs' current Construction In Progress is ₹0 Mil. Overall, Aarti Pharmalabs has a GF Score™ of 54/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aarti Pharmalabs' Construction In Progress compare to ZTS?
Aarti Pharmalabs' Construction In Progress of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Aarti Pharmalabs and its competitors. Aarti Pharmalabs's current Construction In Progress is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Pharmalabs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Pharmalabs (NSE:AARTIPHARM) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹689.04, compared to a current price of ₹888.70 — trading 29% above its estimated fair value. The current Construction In Progress is ₹0 Mil. Aarti Pharmalabs' overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Aarti Pharmalabs (NSE:AARTIPHARM), the current Construction In Progress is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aarti Pharmalabs (NSE:AARTIPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Pharmalabs stock appears to be overvalued. The current stock price of ₹888.70 is trading 29% above its estimated GF Value™ of ₹689.04. GuruFocus considers Aarti Pharmalabs to be Modestly Overvalued.

Key valuation signals for NSE:AARTIPHARM:

  • Construction In Progress: ₹0 Mil
  • GF Value™: ₹689.04 vs. price of ₹888.70 (29% above fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the NSE:AARTIPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aarti Pharmalabs Business Description

Other Exchanges 543748:India
Address Mulund Goregaon Link Road, 204, 2nd Floor, Udyog Kshetra, Mulund West, Mumbai, MH, IND, 400080
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
54GF Score

Get the complete analysis for NSE:AARTIPHARM

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹888.70
Price
₹689.04
GF Value